title: [Clinical evaluation of calculating carboplatin doses using modification of diet in renal disease (MDRD) estimate and adverse events].
abstract: A modified diet in renal disease (MDRD), a formula to estimate glomerular filtration rate (GFR), was proposed by Levey in 2006. In this study, we compared the dosage of carboplatin (CBDCA) calculated using MDRD with that calculated by conservative creatinine clearance (Ccr), and investigated the actual dosage given and the incidence of its adverse effects. In the 101 patients undergoing chemotherapy including CBDCA, the dosage calculated from the estimated GFR was 16% lower than that based on the estimated Ccr. This difference was greater in those under 65 years, women and those with a body mass index (BMI) > or =25. The most prominent incidence of adverse effects was thrombocytopenia in patients with lung cancer. In men, a serum creatinine level of > or =0. 6 mg/dL, GFR of <50 mL/min/1. 73 m(2) and a combined use of gemcitabine were cited as the factors responsible for the development of thrombocytopenia. It was concluded that the MDRD formula is an effective tool for evaluating patients with impaired renal function. It was suggested, on the other hand, that the dosage for medication should be decided by giving due consideration to factors other than renal functions.
authors.affiliation: Dept. of Pharmacy, Gifu Municipal Hospital.
authors.forename: Yuka
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Rie
authors.initials: R
authors.lastname: Matsumoto
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Yoshimura
authors.forename: Toshiya
authors.initials: T
authors.lastname: Nakao
authors.forename: Michio
authors.initials: M
authors.lastname: Kimura
authors.forename: Eiseki
authors.initials: E
authors.lastname: Usami
authors.forename: Kazutomo
authors.initials: K
authors.lastname: Okada
authors.forename: Shino
authors.initials: S
authors.lastname: Adachi
authors.forename: Tomoko
authors.initials: T
authors.lastname: Matsuoka
authors.forename: Tadashi
authors.initials: T
authors.lastname: Yasuda
mesh_terms: D000367:Age Factors; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects; D003404:Creatinine / Q000378:metabolism; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012737:Sex Factors; D013921:Thrombocytopenia / Q000139:chemically induced; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D003841:Deoxycytidine; D003404:Creatinine; D016190:Carboplatin; D000093542:Gemcitabine